5th Annual Meeting of the ASCCT
September 29-30, 2016
Research Triangle Park, NC
- Two themed sessions: Read Across and Pluripotent Stem Cells (PSCs)
- Panel discussion on PSCs
- Free communications chosen from submitted abstracts
- Poster session & Mentoring activity
- Social reception and awards ceremony
Click here for abstract submission, registration, and program details. Abstracts for poster presentations accepted until end of the day August 31.
October 2-6, 2016
Abstract Submission deadline: April 30, 2016
October 17-20, 2016
Abstract submission deadline: May 15, 2016
- Emerging technologies for in vitro tissue/organ toxicity testing
- Extrapolation dose / modelling
- Systemic toxicity
- Endocrine disruption
- Regulatory updates (validation, ITS, regulatory application)
- Rapid 3D Bioprinting: an Enabling Technology for Creating Functional Tissue Models | Shaochen Chen, University of California, San Diego
- Human Primary In Vitro Systems for Translational Drug Safety and Mechanisms of Toxicity | Ellen Berg, Bioseek/DiscoverX
- Integrating in silico predictions with PBPK modeling | Michael Lawless, SimulationsPlus, Inc.
- The GARD assay for skin and respiratory sensitization | Andy Forreryd, Lund University
- COSMOS: Automated in silico tools for in vitro to in vivo extrapolation| Alicia Paini, European Commission Joint Research Centre
- Threshold of Toxicological Concern â€“ an approach for safety assessment and its applicability to cosmetics-related chemicals | Chihae Yang, Altamira, LLC and Molecular Networks
- Medical Device Irritation Testing: An In Vitro Alternative | Kelly Coleman, Medtronic Biomaterials Dept
- Developing Confidence in 21st-Century Risk Assessments | Craig Rowlands, Dow Chemical Company
- COSMOS DB: A New Database of Toxicological Information to Support Knowledge Discovery | Mark Cronin, Liverpool John Moores University and COSMOS project coordinator
- High Content Imaging Approaches in Neurotoxicology and Neurodegeneration Research | Marcel Leist, University of Konstanz and CAAT Europe
- EURL ECVAM's Approach to Validation of Alternative Methods | Valerie Zhuang, EURL ECVAM
- Using the AOP Framework to Develop HTS Assays for Thyroid-Disrupting Chemicals | Katie Paul, US EPA
- The Role of Non-Animal Methods in the Regulation of Nanomaterials in the United States | Erik Janus, Steptoe and Johnson LLP (Recording not available)
- Human Induced Pluripotent Stem Cell-derived Model Systems | Maureen Bunger, Cellular Dynamics
- Incorporating New Technologies into Toxicity Testing and Risk Assessment | Russell Thomas, The Hamner Institutes for Health Science
- The Virtual Embryo | Nicole Kleinstreuer, US EPA
- Tox21 Program Update | Raymond Tice, National Toxicology Program, NIH
- Evidence-Based Toxicology (EBT) for the 21st Century | Martin Stephens, Johns Hopkins University
- Effectopedia: The Online Encyclopedia of Adverse Effect Pathways | Gilman Veith and Hristo Aladjov, International QSAR Foundation
- MetaPath: A Metabolism Pathway Database | Patricia Schmeider, US EPA
Fourth Annual Scientific Meeting of the American Society for Cellular and Computational Toxicology: Promises and Challenges of a More Flexible Approach to Toxicology Testing
The fourth annual ASCCT meeting explored new approaches to toxicology testing with plenary lectures given by Warren Casey, Director of NICEATM and Craig Rowlands from the Dow Chemical Company. The meeting featured a diverse poster session, a panel discussion on the assessment and application of IATA, and ten oral presentations chosen from a very competitive field of abstracts. Members elected two new members to the Board of Directors: Gertrude-Emilia Costin and Shaun McCullough. View Program. ASCCT members, click here to view all presentations.
Third Annual Scientific Meeting of the American Society for Cellular and Computational Toxicology: Where Chemistry and Biology Meet: AOPs as a Framework for Advancing Toxicology
Dr. Robert Kavlock of the US Environmental Protection Agency opened the meeting with a discussion on the development of the Adverse Outcome Pathways concept, in which AOPs offer a biological context to facilitate the development of Integrated Approaches to Testing and Assessment (IATA) for regulatory decision-making. Drs. Jennie Larkin and Ajay Pillai from NIH discussed BD2K and LINCS, two community-building programs. Other presenters explored the development of different tools used to test toxicity. A poster session and reception concluded the meeting. View Program. ASCCT members, click here to view all presentations.
Second Annual Scientific Meeting of the American Society for Cellular and Computational Toxicology: The Future Is Here: Practical Applications of Emerging Scientific Tools
Human Organs on Chips as Replacements for Animal Testing, the keynote address given by Donald E. Ingber, M.D., Ph.D., of the Wyss Institute at Harvard, kicked off the meeting which featured a dozen lectures and poster presentations on making toxicology a more human-relevant science. Other topics included methods to replace live animals in eye irritation tests and computer-based virtual embryos that show how chemical exposures might affect developing embryos. View Program.
First Annual Scientific and Business Meeting of the ASCCT
The first annual ASCCT meeting focused on advances in the fields of in vitro and computational toxicology. Dr. Melvin Andersen, associate director of The Institute for Chemical Safety Sciences at The Hamner Institutes for Health Sciences and ASCCT board member, gave a plenary lecture on Computational Cellular Pathway Modeling: Combining Key In Vitro and In Silico Tools to Enhance Modern Safety Assessment. Dr. Suzanne Fitzpatrick, senior advisor for toxicology at the U.S. Food and Drug Administration gave a plenary lecture on an Overview of the FDA-DARPA-NIH Collaboration on Human/Organ on a Chip. View Program.
Institute for In Vitro Sciences Practical Methods for In Vitro Toxicology Workshop
Attendees gained hands-on laboratory experience and instruction in the practical application of the lectured topics. Topics for the three and a half day course included: (i) international regulatory acceptance status of in vitro assays, (ii) predicting organ specific toxicity (e.g., ocular, dermal and hepatic), (iii) using cell and organ culture models with histological, biochemical, and molecular endpointsm, and (iv) data interpretation.
2010 In Vitro Alternatives Forum
Thank you for contributing to a successful forum. Read the post-meeting report.
8th World Congress for Alternatives and Animal Use
Thank you for helping to make the ASCCT/ESTIV luncheon session a success. A manuscript outlining the discussions that took place during the session has been published. You can view the entire proceedings here.